272 related articles for article (PubMed ID: 16293957)
1. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
Foley RJ; Metersky ML
Respiration; 2008; 75(2):211-4. PubMed ID: 16293957
[TBL] [Abstract][Full Text] [Related]
2. Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists?
Pitsiou GG; Spyratos D; Kioumis I; Boutou AK; Nakou C; Stanopoulos I
Ther Adv Respir Dis; 2009 Jun; 3(3):99-101. PubMed ID: 19638368
[TBL] [Abstract][Full Text] [Related]
3. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
4. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade.
Sharma S; Kashour T; Philipp R
Tex Heart Inst J; 2005; 32(3):405-10. PubMed ID: 16392231
[TBL] [Abstract][Full Text] [Related]
5. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
6. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
7. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
Baughman RP; Culver DA; Cordova FC; Padilla M; Gibson KF; Lower EE; Engel PJ
Chest; 2014 Apr; 145(4):810-817. PubMed ID: 24177203
[TBL] [Abstract][Full Text] [Related]
8. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
9. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
[TBL] [Abstract][Full Text] [Related]
10. [Long-term therapy with endothelin-1 antagonist for pulmonary hypertension secondary to systemic sclerosis].
Shalev L; Langevitz P; Zandman-Goddard G
Harefuah; 2008 Apr; 147(4):287-9, 376. PubMed ID: 18686806
[TBL] [Abstract][Full Text] [Related]
11. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological characteristics and clinical efficacy of bosentan].
Fujimoto K; Ikenoya S
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):407-18. PubMed ID: 16462092
[No Abstract] [Full Text] [Related]
13. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
14. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
15. Bosentan therapy for portopulmonary hypertension.
Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
Nakwan N; Choksuchat D; Saksawad R; Thammachote P; Nakwan N
Acta Paediatr; 2009 Oct; 98(10):1683-5. PubMed ID: 19523174
[TBL] [Abstract][Full Text] [Related]
17. [Bosentan for treatment of heart failure].
Yoshimoto T; Hirata Y
Nihon Rinsho; 2007 May; 65 Suppl 5():159-63. PubMed ID: 17571378
[No Abstract] [Full Text] [Related]
18. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Nishibu A; Sakai E; Oyama N; Yamamoto T
Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
[TBL] [Abstract][Full Text] [Related]
19. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
[No Abstract] [Full Text] [Related]
20. Endothelin-I receptor antagonist for the treatment of pulmonary arterial hypertension in systemic sclerosis.
Varga J
Curr Rheumatol Rep; 2003 Apr; 5(2):145-6. PubMed ID: 12628045
[No Abstract] [Full Text] [Related]
[Next] [New Search]
